Essential tremor is judged mostly the way it has been for decades: a neurologist watches a patient hold out a hand or draw a spiral for a few minutes and writes down a number. On November 17, Sine Health said FDA had cleared its app to do something different, measuring tremor in the background of an ordinary day using only the sensors already in a patient's smartphone.
That is a narrow regulatory claim with a large practical question behind it. Monitoring is not diagnosis and it is not treatment, and a 510(k) clearance is not proof that the numbers change care. In this deep dive we set out what FDA's own records show, what evidence is public, how the cleared product compares with the other things cleared for essential tremor, and what a neurology practice or trial sponsor should ask before relying on a phone-derived tremor score.
The clearance says the software may be marketed for monitoring. Whether the number changes a decision is a separate question.
In This Deep Dive
- Why this matters now
- What actually happened
- The obvious read versus the deeper signal
- Category map and taxonomy
- Evidence Ladder
- What FDA's pathway does and does not cover
- Capital flows and bottom-up economics
- The HealthTech Investor's Signal
- Counter-thesis
- Forward Intelligence
- The Bottom Line for Neurology Practices, Trial Sponsors and Digital Health Investors
Why this matters now
Sine's founder and CEO, Jakob Gerstl, said in the company's announcement that with several new therapies for essential tremor arriving, the need to measure how patients actually do at home is growing. The company also says clinicians largely judge tremor from brief, intermittent observation in the clinic, and that patients are often not optimized on medication or surgery. Those are company statements, but the structural point is hard to dispute: a condition with fluctuating symptoms is assessed at a few fixed moments.
The timing has a concrete anchor. Praxis Precision Medicines announced on April 14, 2026 that FDA accepted its new drug application for ulixacaltamide for essential tremor in adults, with a PDUFA target action date of January 29, 2027 and no advisory committee meeting planned. The application rests on the Essential3 Phase 3 program, and the drug received Breakthrough Therapy Designation in December 2025. If an approval comes, neurologists will want a way to see whether a patient's tremor actually changed after a new prescription.
The device also sits in a wider shift in how FDA treats sensor-based software. Sine's earlier clearance for Parkinson's disease, issued on June 17, 2026, shows the template: take a signal from a consumer device, derive a tremor score, show the trend to a clinician, and clear it as a Class II tremor transducer. The November clearance extends that template from a watch to a phone and from Parkinson's disease to essential tremor.
Certainty: (A) Praxis dates and designations are from the Praxis release; (A) device dates, numbers and classification are from FDA records; (A) quotes and the 7 million figure are attributed to Sine and are company statements; (B) our reading that a drug approval would raise demand for objective home measurement.
What actually happened
- The announcement: Sine Health announced FDA 510(k) clearance for Sine, its smartphone-based essential tremor monitoring system, on November 17, 2026 from Stockholm. The company says the app measures tremor passively as patients go about their day, "like a step counter," and gives clinicians an objective view of how tremor changes between visits.
- What FDA records show: FDA lists the device as Sine Monitoring Essential Tremor Smartphone, 510(k) number K261026, applicant Nordic Kinetics AB of Lund, Sweden. FDA received the submission on March 30, 2026 and issued a decision of substantially equivalent on November 15, 2026, a traditional 510(k) reviewed by the Neurology panel, not by a third party, with no predetermined change control plan authorized and no combination product. We did not find the 510(k) summary for K261026 on FDA's site.
- The company: Sine Health, formerly Nordic Kinetics, says it is building a continuous, objective, AI-based neurological examination from smartphone and wearable sensor streams. It says the November clearance is its second since it was founded last year, after a June 2026 clearance for Parkinson's disease monitoring using Apple Watches.
- The claims: Sine says it is the first FDA-cleared way to monitor essential tremor using only a smartphone and that essential tremor affects about 7 million Americans. We have not independently verified either figure; the first is a first-of-its-kind claim we could only check against the database entry, which does not state it.
- The public study: A 2026 abstract by Gerstl and S. Grigoriou at the International Congress of Parkinson's and Movement Disorders describes a passive smartphone method tested in 42 essential tremor patients and 7 controls at a neurology clinic in southern Sweden. The abstract does not say it is the clearance dataset.
Certainty: (A) FDA database fields and the announcement text, attributed in the paragraph; (A) the abstract's numbers as published in the abstract; (C) whether the abstract and the clearance share data, which neither document states.

The obvious read versus the deeper signal
The obvious read: A Swedish startup got a phone app cleared, and the news is that essential tremor can now be tracked with a smartphone. On this reading the story is a first-of-its-kind product launch and the right response is to see how fast clinics adopt it.
The deeper signal: The more useful reading is about what the clearance is for. FDA cleared a monitoring and quantification tool, so the claim is about measuring tremor, not about deciding treatment or diagnosing the condition. The value will depend on whether a phone-derived score is stable enough to compare a patient before and after a therapy, and whether clinicians and trial sponsors accept it as a measure. That evidence is not yet public, and the first test may come with a new drug decision.
Certainty: (B) evidence-based interpretation; the clearance text and indications for K261026 were not available to us, and the abstract is not a peer-reviewed full paper.
Historical playbook
Tremor has a short list of cleared tools, and most treat it rather than measure it. Insightec's ExAblate Neuro, an MR-guided focused ultrasound system, was approved by FDA on July 11, 2016 for unilateral thalamotomy in patients aged 22 or older with idiopathic essential tremor and medication-refractory tremor, and a labeling change to its indications was approved on December 8, 2022. Cala Health's Cala ONE wearable stimulator was classified through a De Novo order on April 26, 2018 to aid in the transient relief of hand tremors in adults with essential tremor, and its successor Cala kIQ was cleared on November 22, 2022 under K222237.
Measurement has a separate history. In February 2021, Apple researchers led by Rob Powers published a study in Science Translational Medicine of the Motor Fluctuations Monitor for Parkinson's Disease, or MM4PD. It was tested in 343 patients, 225 of whom were followed for six months, and AAAS reported that its evaluations matched a clinician's estimates in 94% of the subjects. Rune Labs' Kinematics System (K213519) and a second app cleared as K220820 built on that toolkit, and Sine's June 2026 clearance used both as predicates. Sine's November clearance is different in kind because it relies on phone accelerometer data rather than a watch.











